UGT8-IN-1 是能透过血脑屏障的、具有口服活性的神经酰胺半乳糖转移酶 (UGT8) 的抑制剂，可用于溶酶体储存障碍的研究。

UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders.

Solid

UGT8-IN-1 (compound 19) exhibits the T1/2 of 4.3 h, 1.13 h and 13.6 h by iv (1 mg/kg) administration in rat, mouse and dog, respectively. UGT8-IN-1 (compound 19) shows F% of 40%, 34% and 52% by oral (3 mg/kg) administration in rat, mouse and dog, respectively.
UGT8-IN-1 (compound 19, orally twice a day for three days) shows ≥90% inhibition of incorporation of C-Gal into GalCer and SFT, at all three doses tested, with the estimated ED 50 s of <3 mg/kg for inhibition of both SFT and GalCer. UGT8-IN-1 (compound 19) has very high plasma protein and tissue binding (>99%).
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

[1]. Sukanthini Thurairatnam, et al. Brain Penetrable Inhibitors of Ceramide Galactosyltransferase for the Treatment of Lysosomal Storage Disorders. ACS Med Chem Lett. 2020 Jun 16;11(10):2010-2016.

In Vitro: DMSO : 115 mg/mL (217.61 mM; Need ultrasonic)配制储备液